TapImmune to Present at Two Upcoming Investor Conferences
JACKSONVILLE, Fla., Sept. 25, 2018 /PRNewswire/ -- TapImmune Inc. (NASDAQ :TPIV ), a clinical-stage immuno-oncology company, today announced that its President and CEO, Peter L. Hoang, will participate at two upcoming investor conferences. Mr. Hoang will present at the Cantor Global Healthcare Conference, to be held October 1-3, 2018, in New York City, and will present and participate in Advances in Cell and Gene Therapies Panel at the Sachs Associates 18th Annual Biotech in Europe Forum, to be held October 4-5, 2018, in Basel, Switzerland.
Cantor Global Healthcare Conference:
Date: Monday, October 1, 2018
Location: Intercontinental New York Barclay Hotel; New York, NY
Time: 3:30pm (ET): Track 6 – Rockefeller Suite
Sachs Associates 18th Annual Biotech in Europe Forum
Date: Thursday, October 4, 2018
Location: The Congress Center Basel; Basel, Switzerland
Time: 11:30am (CEST): Panel - Advances in Cell & Gene Therapies
4:05pm (CEST): Company Presentation
Both events will be webcast, available at https://tapimmune.com/events/.
About TapImmune Inc.
TapImmune Inc. is a leader in the development of novel immunotherapies for cancer, with multiple Phase 2 and Phase 1b/2 clinical studies currently ongoing for the treatment of ovarian and breast cancer. The Company's peptide or nucleic acid-based immunotherapeutic products comprise multiple naturally processed epitopes (NPEs) that are designed to comprehensively stimulate a patient's killer T cells and helper T cells, and to restore or further augment antigen presentation using proprietary nucleic acid-based expression systems. This unique approach can produce off-the-shelf T cell vaccine candidates that elicit a broad-based T cell response and can be used without respect to HLA type. The Company's technologies may be used as stand-alone medications or in combination with other treatment modalities. TapImmune has announced a proposed merger with Marker Therapeutics, Inc., a privately-held clinical stage developer of a transformative, non-genetically engineered, multi-antigen T cell therapy platform, which will add a significant portfolio of clinical-stage cell therapies to create a leading immuno-oncology pipeline.
For additional information, please visit: https://tapimmune.com/
To receive future press releases via email, please visit:
Follow us on Twitter @Tapimmune_Inc, or follow us on Facebook.
For answers to frequently asked questions, please visit our FAQs page: https://tapimmune.com/investors/frequently-asked-questions/
Forward-Looking Statement Disclaimer
This release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company's expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are "forward-looking statements". Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stored in such statements. Such risks, uncertainties and factors include, but are not limited to the results of the Phase 2 clinical trials, the ability to obtain regulatory approval of TPIV200, the Company's ability to raise future financing for continued development and the ability to successfully commercialize TPIV200 as well as the risks and uncertainties set forth in the Company's most recent Form 10-K, 10-Q and other SEC filings which are available through EDGAR at www.sec.gov. The Company assumes no obligation to update the forward-looking statements.